Tenofovir, Emtricitabine and Efavirenz Late Switch to a Single Pill: Patients' Opinion Survey

• Patient adherence [ Time Frame: V0, V1, V2 ] [ Designated as safety issue: No ]
  by questionnaire in both subgroups and by MEMS data in the adherence subgroup
  
  
• Adverse events and symptoms [ Time Frame: V0, V1, V2 ] [ Designated as safety issue: No ]
  by questionnaires
  
  
• Treatment management [ Time Frame: V0, V1, V2 ] [ Designated as safety issue: No ]
  Treatment management according to meals, timing, disruptive daily schedule By questionnaire
  
  
• Patient satisfaction of the switch [ Time Frame: V1, V2 ] [ Designated as safety issue: No ]
  By questionnaire
  
  

• Impact of switch on clinical outcomes [ Time Frame: V0, V1, V2 ] [ Designated as safety issue: No ]
  Clincal outcomes = viral load, CD4 count, resistance, EFV blood level. By medical file
  
  
• Patients' acceptance of switch [ Time Frame: V-1 ] [ Designated as safety issue: No ]
  

Each eligible patient will be screened from de SHCS database. Each refusal and drop-out will be documented. A pre-visit (V-1) will be scheduled for informed consent, V0 for inclusion (V-1 and V0 may occur on the same day), V1 one month post-inclusion and V2 4 to 7 months post-inclusion. V0, V1 and V2 will be planned during regular medical visits.

Eligible patients either get their cART in their usual pharmacy according to standard of care, or take part in a routine adherence-enhancing program(adherence subgroup)run by the pharmacists of the outpatient medical clinic.

In the adherence subgroup, adherence is assessed electronically by MEMS (Medication event monitoring system) monitors on a regular basis.